Patients with hematological neoplasms vs matched controls
| No. of patients . | COVID-19 outcome . | Patients affected, N . | Controls affected, N . | Relative risk . | Confidence interval . |
|---|---|---|---|---|---|
| All patients with hematological neoplasms (n = 32 156) | Infection | 106 | 64 | 1.60 | 1.12-2.37 |
| Symptomatic | 68 | 35 | 1.72 | 1.05-2.85 | |
| Hospitalized | 50 | 15 | 3.13 | 1.68-7.08 | |
| Severe | 40 | 17 | 2.27 | 1.18-5.19 | |
| Death | 23 | 13 | 1.66 | 0.72-4.47 | |
| Patients on treatment (n = 5107) | Infection | 37 | 9 | 2.74 | 1.31-8.99 |
| Symptomatic | 27 | 5 | 3.09 | 1.20-20.81 | |
| Hospitalized | 22 | 3 | 10.81 | 3.80-41.78 | |
| Severe | 19 | 3 | 8.97 | 3.13-35.07 | |
| Death | 13 | 1 | 19.31 | 3.95-30.72 | |
| Patients without treatment (n = 27 049) | Infection | 78 | 55 | 1.38 | 0.93-2.15 |
| Symptomatic | 46 | 31 | 1.29 | 0.76-2.28 | |
| Hospitalized | 30 | 14 | 1.97 | 0.97-4.61 | |
| Severe | 23 | 14 | 1.66 | 0.70-4.00 | |
| Death | 12 | 11 | 1.40 | 0.43-4.49 |
| No. of patients . | COVID-19 outcome . | Patients affected, N . | Controls affected, N . | Relative risk . | Confidence interval . |
|---|---|---|---|---|---|
| All patients with hematological neoplasms (n = 32 156) | Infection | 106 | 64 | 1.60 | 1.12-2.37 |
| Symptomatic | 68 | 35 | 1.72 | 1.05-2.85 | |
| Hospitalized | 50 | 15 | 3.13 | 1.68-7.08 | |
| Severe | 40 | 17 | 2.27 | 1.18-5.19 | |
| Death | 23 | 13 | 1.66 | 0.72-4.47 | |
| Patients on treatment (n = 5107) | Infection | 37 | 9 | 2.74 | 1.31-8.99 |
| Symptomatic | 27 | 5 | 3.09 | 1.20-20.81 | |
| Hospitalized | 22 | 3 | 10.81 | 3.80-41.78 | |
| Severe | 19 | 3 | 8.97 | 3.13-35.07 | |
| Death | 13 | 1 | 19.31 | 3.95-30.72 | |
| Patients without treatment (n = 27 049) | Infection | 78 | 55 | 1.38 | 0.93-2.15 |
| Symptomatic | 46 | 31 | 1.29 | 0.76-2.28 | |
| Hospitalized | 30 | 14 | 1.97 | 0.97-4.61 | |
| Severe | 23 | 14 | 1.66 | 0.70-4.00 | |
| Death | 12 | 11 | 1.40 | 0.43-4.49 |